Menu Search
Equities

Integra Lifesciences Holdings Corp

IL3:FRA

Integra Lifesciences Holdings Corp

Actions
  • Price (EUR)15.60
  • Today's Change-0.20 / -1.27%
  • Shares traded100.00
  • 1 Year change-57.38%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Integra Lifesciences Holdings Corp's net income fell -62.48% from 180.55m to 67.74m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 38.25% to 39.09%.
Gross margin61.54%
Net profit margin1.51%
Operating margin4.04%
Return on assets0.60%
Return on equity1.47%
Return on investment0.66%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Integra Lifesciences Holdings Corp fell by 180.26m. However, the company earned 139.96m from its operations for a Cash Flow Margin of 9.08%. In addition the company used 94.18m on investing activities and also paid 229.93m in financing cash flows.
Cash flow per share1.95
Price/Cash flow per share8.89
Book value per share19.77
Tangible book value per share-10.19
More ▼

Balance sheet in USDView more

Integra Lifesciences Holdings Corp has a Debt to Total Capital ratio of 54.33%, a lower figure than the previous year's 79.22%.
Current ratio3.39
Quick ratio2.10
Total debt/total equity1.19
Total debt/total capital0.5433
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)3.10
EPS (TTM) vs
TTM 1 year ago		-81.27
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.